Search

Brendan B Magrab

from Far Hills, NJ
Age ~59
Get Report
Also known as:
Edward Brendan Magrab, Edward B Magrab, Edward D Magrab, Brenoon Magrab, Phyllis R Magrab
Phone and address:
94 Annin Rd, Far Hills, NJ 07931
Related to:
Robert P Coleman, 81
Connected to:
Howard M Magrab, 82Phyllis R Magrab, 84Julie A Magrane, 57Kelly A Magrane, 56Lynessa A Magrans, 35Sean Magrath, 50Susan M Magrath, 55Joe J Magrey, 49Rhonda S Magrey, 69Carmen M Magri, 78

Brendan Magrab Phones & Addresses

  • 94 Annin Rd, Far Hills, NJ 07931
  • 437 Dudley Ave, Westfield, NJ 07090 (908) 301-9333 (908) 301-9339
  • Winhall, VT
  • Arlington, VT
  • Washington, DC
  • Bethesda, MD
  • 437 E Dudley Ave, Westfield, NJ 07090 (908) 301-9333

Work

Company: Hedgepath pharmaceuticals Dec 2016 to Jun 2019 Position: Chairman of the board

Education

Degree: Doctor of Jurisprudence, Doctorates School / High School: Georgetown University Law Center 1989 to 1992 Specialities: Law

Industries

Pharmaceuticals

Resumes

Resumes

Brendan Magrab Photo 1

Chief Executive Officer

View page
Location:
94 Annin Rd, Far Hills, NJ 07931
Industry:
Pharmaceuticals
Work:
Hedgepath Pharmaceuticals Dec 2016 - Jun 2019
Chairman of the Board
Epalex Corporation Dec 2016 - Jun 2019
Chief Executive Officer
Transpharmative Advisors Dec 2016 - Jun 2019
President
Url Pharma 2012 - Feb 2013
President and Chief Executive Officer
Url Pharma, Inc. 2004 - Jul 2012
Executive Vice President of Commercial Operations and General Counsel
Education:
Georgetown University Law Center 1989 - 1992
Doctor of Jurisprudence, Doctorates, Law University of Virginia 1983 - 1987
Bachelors, Bachelor of Arts, Biochemistry, Art History

Publications

Us Patents

Compositions And Methods To Inhibit Kidney Stone Growth

View page
US Patent:
20200054707, Feb 20, 2020
Filed:
Oct 25, 2019
Appl. No.:
16/663675
Inventors:
- Fort Lauderdale FL, US
Brendan Magrab - Westfield NJ, US
Henry R. Wolfe - Glenmoore PA, US
International Classification:
A61K 36/88
A61K 33/06
A61K 31/6615
A61K 31/4415
A61K 31/194
A61K 9/48
A61K 9/00
Abstract:
An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.

Compositions And Methods To Inhibit Kidney Stone Growth

View page
US Patent:
20180008660, Jan 11, 2018
Filed:
Sep 20, 2017
Appl. No.:
15/710306
Inventors:
- Fort Lauderdale FL, US
Brendan Magrab - Westfield NJ, US
International Classification:
A61K 36/88
A61K 31/4415
A61K 31/194
A61K 31/6615
A61K 9/00
Abstract:
An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.

Compositions And Methods To Inhibit Kidney Stone Growth

View page
US Patent:
20170216388, Aug 3, 2017
Filed:
Apr 14, 2017
Appl. No.:
15/487735
Inventors:
- Fort Lauderdale FL, US
Brendan Magrab - Westfield NJ, US
International Classification:
A61K 36/88
A61K 9/00
A61K 31/4415
A61K 31/194
A61K 31/6615
Abstract:
An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.

Compositions And Methods To Inhibit Kidney Stone Growth

View page
US Patent:
20170065657, Mar 9, 2017
Filed:
Dec 7, 2015
Appl. No.:
14/960692
Inventors:
- Fort Lauderdale FL, US
Brendan Magrab - Westfield NJ, US
International Classification:
A61K 36/88
A61K 9/48
A61K 31/4415
A61K 9/00
A61K 31/194
A61K 31/6615
Abstract:
An oral dosage form or plurality of oral dosage forms comprising as active ingredients citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.

Compositions And Methods To Inhibit Kidney Stone Growth

View page
US Patent:
20170065658, Mar 9, 2017
Filed:
Sep 15, 2016
Appl. No.:
15/266464
Inventors:
- Fort Lauderdale FL, US
Brendan Magrab - Westfield NJ, US
International Classification:
A61K 36/88
A61K 33/06
A61K 9/48
A61K 31/4415
A61K 9/00
A61K 31/194
A61K 31/6615
Abstract:
An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.
Control profile
Brendan B Magrab from Far Hills, NJ, age ~59 Get Report